| omecamtiv mecarbil (AMG 423) / Amgen, Servier |
2020-003057-30: Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF |
|
|
| Not yet recruiting | 3 | 1286 | Europe | Omecamtiv mecarbil, AMG 423, Modified-release tablet | Amgen Inc., Amgen Inc. | Chronic heart failure with reduced ejection fraction, Chronic Heart Failure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| reldesemtiv (CK-2127107) / Astellas, Cytokinetics |
| Terminated | 3 | 486 | Europe, Canada, US, RoW | Reldesemtiv, Placebo | Cytokinetics | Amyotrophic Lateral Sclerosis | 07/23 | 07/23 | | |
| Terminated | 3 | 71 | Europe, Canada, US, RoW | Reldesemtiv | Cytokinetics, Cytokinetics Inc | Amyotrophic Lateral Sclerosis | 06/23 | 06/23 | | |
| aficamten (CK-274) / Cytokinetics |
| Completed | 3 | 282 | Europe, US, RoW | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match CK-3773274 | Cytokinetics, Corxel Pharmaceuticals | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 12/23 | 12/23 | | |
|
|
MAPLE-HCM, NCT05767346: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM |
|
|
| Active, not recruiting | 3 | 175 | Europe, Canada, US, RoW | Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate | Cytokinetics | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 07/25 | 10/25 | | |
NCT06116968: An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM |
|
|
| Recruiting | 3 | 44 | RoW | Aficamten, CK-3773274 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Obstructive Hypertrophic Cardiomyopathy | 03/26 | 03/26 | | |
ACACIA-HCM, NCT06081894: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM |
|
|
| Recruiting | 3 | 420 | Europe, US, RoW | Aficamten, Placebo | Cytokinetics | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 06/26 | 09/26 | | |
CEDAR-HCM, NCT06412666: A Study to Evaluate the Effect of Aficamten in Pediatric Patients (Age 12 to <18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). |
|
|
| Recruiting | 2/3 | 40 | US | Aficamten, Placebo | Cytokinetics | Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | 12/28 | 12/28 | | |
| Enrolling by invitation | 2/3 | 900 | Europe, US, RoW | Aficamten (5 - 20 mg) | Cytokinetics | Symptomatic Hypertrophic Cardiomyopathy (HCM) | 03/28 | 03/28 | | |
|
|
|
| Completed | 2 | 96 | Europe, US | CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274 | Cytokinetics | Hypertrophic Cardiomyopathy (HCM) | 02/23 | 02/23 | | |
|
|
|
|
|
|
NCT05924815: Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval |
|
|
| Completed | 1 | 44 | US | Aficamten, Aficamten-matching Placebo, Moxifloxacin | Cytokinetics | Healthy Participants | 11/23 | 11/23 | | |
| CK-136 / Cytokinetics |
NCT05662215: A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants |
|
|
| Terminated | 1 | 57 | US | CK-3828136, Placebo for CK-3828136 | Cytokinetics | Healthy Participants | 08/23 | 08/23 | | |
| CK-271 / Cytokinetics |
| No trials found |
| Undisclosed skeletal muscle activators / Cytokinetics |
| No trials found |
